Trial Profile
NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 17 Mar 2021
Price :
$35
*
At a glance
- Drugs Brachyury peptide vaccine (Primary) ; CST 101 (Primary) ; ETBX 021 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary) ; GI 4000 (Primary) ; Inbakicept (Primary) ; Avelumab; Bevacizumab; Capecitabine; Cyclophosphamide; Fluorouracil; Folinic acid; Fulvestrant; Omega-3-acid ethyl esters; Oxaliplatin; Paclitaxel
- Indications Carcinoma; Ovarian cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors ImmunityBio
- 23 Aug 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 26 Oct 2017 Planned initiation date changed from 1 Sep 2017 to 1 Dec 2017.
- 27 Jun 2017 New trial record